Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) unveiled NASARIX™ on Feb 17, 2026, branding its lead intranasal allergy product and completing U.S. and European trademark screening. NASARIX™ uses Capture and Contain™ hydrogel to form a drug‑free nasal barrier; preclinical data show superior allergen blocking versus common comparators. A human factors/usability study began Jan 22, 2026, and clinical trials are expected to start in Q3 2026, with the company positioning NASARIX™ as a medical device to pursue a streamlined regulatory path.

Positive

• Branding & trademark completed in U.S. and Europe (Feb 17, 2026)
• Human factors/usability study initiated Jan 22, 2026
• Preclinical data show better allergen blocking vs hydroxypropyl methylcellulose
• Company is positioning NASARIX™ as a medical device to pursue streamlined approval

Negative

• Product remains preclinical with no human efficacy or safety data yet
• Human clinical trials are only expected Q3 2026, creating near‑term timing risk
• Press release is a paid promotional communication, indicating potential conflicts of interest

Key Figures

Global allergic rhinitis prevalence: 10–30% of global population U.S. patients: Over 60 million people per year Market size 2025: USD 13.08 billion +5 more

8 metrics

Global allergic rhinitis prevalence 10–30% of global population Burden of allergic rhinitis

U.S. patients Over 60 million people per year Allergic rhinitis impact in U.S.

Market size 2025 USD 13.08 billion Allergic rhinitis treatments, 2025 estimate

Market size 2035 USD 18.81 billion Allergic rhinitis treatments, 2035 projection

CAGR 3.7% 2025–2035 allergic rhinitis market growth

Alt. market 2024 USD 12.24 billion Alternative estimate, 2024 market size

Alt. market 2033 USD 16.97 billion Alternative projection, 2033 market size

Clinical trial timing Q3 2026 Planned start of NASARIX™ clinical trials

Market Reality Check

Price: $13.85 Vol: Volume 63,432 is below 20...

normal vol

$13.85 Last Close

Volume Volume 63,432 is below 20-day average 85,207 (relative 0.74x), suggesting muted trading interest pre‑news. normal

Technical Shares at $13.85 are trading below the 200-day MA of $48.41 and sit far under the $2,235 52-week high.

Peers on Argus

PLRZ was down about 1% while close biotech peers showed mixed moves: TTNP, ADTX,...

1 Up

PLRZ was down about 1% while close biotech peers showed mixed moves: TTNP, ADTX, SILO and SXTP were negative, whereas ENSC was notably positive. With only one peer in momentum and no consistent direction across names, PLRZ’s action appears stock-specific rather than part of a coordinated sector move.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Aviation stake MOU	Positive	+3.9%	Signed MOU for 51% Arrow Aviation stake with ≈$19M revenue, $3M EBITDA.
Feb 06	Neuroplastogen deal	Positive	+3.3%	Development agreement to create intranasal MEAI formulation with Clearmind Medicine.
Feb 04	Private aviation entry	Positive	-15.2%	MOU to acquire 51% of Arrow Aviation via NIS 18,000,000 cash investment.
Jan 22	NASARIX™ usability study	Positive	-2.0%	Initiation of FDA‑aligned human factors/usability study for NASARIX™ allergy blocker.
Jan 13	Strategic investments plan	Positive	+0.7%	Board authorized exploring revenue‑generating investments leveraging strong cash and no debt.

Pattern Detected

Recent news is generally positive or expansionary, but price reactions have been mixed, including notable selloffs on strategically positive announcements.

Recent Company History

Over the past months, Polyrizon has combined core intranasal pipeline progress with diversification steps. A January 22, 2026 usability study launch for NASARIX™ and pre‑clinical efficacy data underpin today’s branding-focused update. In parallel, the company announced plans to explore revenue‑generating investments and a potential 51% stake in Arrow Aviation with ≈$19M revenue and ≈$3M EBITDA. These moves illustrate a dual track of progressing NASARIX™ while seeking external cash‑flow opportunities.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$50,000,000 registered capacity

Polyrizon has an effective Form F-3 shelf registration filed on November 7, 2025, allowing it to offer up to $50,000,000 of securities (ordinary shares, warrants, and units) from time to time via various distribution methods, with each takedown detailed in a future prospectus supplement. No usage of this shelf has been recorded in the provided context.

Market Pulse Summary

This announcement spotlights NASARIX™’s transition from PL‑14 branding to a defined identity within ...

Analysis

This announcement spotlights NASARIX™’s transition from PL‑14 branding to a defined identity within a $13.08B–$18.81B allergic rhinitis market, emphasizing a drug‑free intranasal barrier approach and FDA‑aligned usability work. It builds on earlier pre‑clinical and regulatory steps and a planned Q3 2026 clinical start. Investors may watch for human efficacy and safety data, execution on the broader strategic initiatives, and any future use of the existing $50,000,000 shelf registration.

Key Terms

allergic rhinitis, compound annual growth rate (CAGR), intranasal, hydrogel, +2 more

6 terms

allergic rhinitis medical

"The Allergic Rhinitis ChallengeAllergic rhinitis- often called hay fever- remains..."

An immune-driven inflammation of the nose and sinuses triggered by allergens such as pollen, dust or pet dander, causing sneezing, congestion, runny nose and itchy eyes. It matters to investors because its prevalence and seasonality affect demand for prescription drugs, over-the-counter treatments, diagnostics and related healthcare services, creating predictable sales cycles and potential market opportunities; think of it as an overly sensitive smoke alarm that drives repeat purchases.

compound annual growth rate (CAGR) financial

"projected to reach USD 18.81 billion by 2035 at a compound annual growth rate (CAGR) of 3.7%."

Compound annual growth rate (CAGR) shows how much an investment grows, on average, each year over a certain period. It’s like measuring how fast a plant grows each year, smoothing out the ups and downs to see the overall growth trend. Investors use CAGR to compare different investments and see which one has the best long-term performance.

intranasal medical

"a pre-clinical-stage biotechnology company developing intranasal protective solutions..."

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

hydrogel medical

"NASARIX™ is a nasal spray based on Polyrizon's Capture and Contain™ (C&C) hydrogel technology."

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

human factors technical

"initiated a key human factors and usability study on January 22, 2026."

Human factors are the study and design of how people interact with products, processes, and work environments to make tasks safer, easier, and less error-prone. For investors, good human factors practices reduce the risk of accidents, product failures, regulatory penalties and costly rework, and can boost productivity and customer satisfaction — much like a well-designed car dashboard that helps drivers operate controls without distraction.

nasal spray medical

"NASARIX™ is a nasal spray based on Polyrizon's Capture and Contain™..."

A nasal spray is a liquid medication delivered directly into the nostrils through a small pump or bottle, allowing drugs to act locally in the nose or absorb into the bloodstream through nasal tissue. Investors watch nasal sprays because they can reach patients quickly, avoid injections, and offer lower manufacturing and distribution costs than some drugs; regulatory approvals, patent protection, and ease of use strongly influence sales potential and risk.

AI-generated analysis. Not financial advice.

HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™. This included trademark screening in the U.S. and European markets and represents a practical step toward potential commercialization for the pre-clinical-stage Israeli biotech.

Polyrizon is assessing whether NASARIX™ could emerge as a meaningful advancement in allergy treatment.

The Allergic Rhinitis Challenge

Allergic rhinitis- often called hay fever- remains a widespread and burdensome condition, affecting an estimated 10–30% of the global population. Symptoms, such as sneezing, nasal congestion, itching, and runny nose, disrupt sleep, work, and daily life, with rising prevalence linked to urbanization, pollution, and climate-driven pollen increases. In the U.S., it impacts over 60 million people each year, contributing to significant healthcare spending and lost productivity.

The global market for allergic rhinitis treatments is substantial and steadily expanding. Recent estimates value it at around USD 13.08 billion in 2025, projected to reach USD 18.81 billion by 2035 at a compound annual growth rate (CAGR) of 3.7%. Other analyses align closely, forecasting growth from USD 12.24 billion in 2024 to USD 16.97 billion by 2033, driven by demand for intranasal therapies and non-sedating alternatives.

Most options are reactive - they relieve symptoms after allergens trigger inflammation. Preventive strategies exist, but few directly block exposure at the nasal entry point in a convenient, drug-free way.

NASARIX™'s Differentiated Approach

NASARIX™ is a nasal spray based on Polyrizon's Capture and Contain™ (C&C) hydrogel technology. When applied, it forms a thin, bio-adhesive barrier that physically traps allergens (such as pollen, dust mites, pet dander) before they reach the sensitive epithelial nasal tissue. Key claimed advantages include:

• Drug-free and non-pharmacological — no steroids, antihistamines, or systemic effects.
• Moisturizing and comfortable for extended use.
• Preclinical lab data show better allergen-blocking than standard comparators (e.g., hydroxypropyl methylcellulose barriers).

If human trials, once initiated, confirm these benefits, it has the potential to appeal to users seeking natural, preventive protection- particularly during peak seasons or in high-exposure environments- without the side effects common in traditional meds.

As of February 2026, the NASARIX™ program continues to advance with encouraging momentum. While human clinical data on efficacy and safety are expected for later this year, Polyrizon has already initiated a key human factors and usability study on January 22, 2026. This important work, fully aligned with FDA guidance, has been shown to validate the product's clear instructions, intuitive labeling, and seamless user experience- steps that significantly strengthen the regulatory foundation and reduce future risks. With this progress in place, the company is expected to begin clinical trials in Q3 2026. Positioning NASARIX™ as a medical device further brightens the potential path ahead, offering a more streamlined and efficient approval route compared to traditional drug development, which brings the possibility of reaching patients, following FDA approval, much sooner.

In a large and steadily growing market hungry for fresh, user-friendly innovations, NASARIX™ represents promise as a proactive, comfortable addition to allergy care. With steady progress, a focused core technology, and upcoming milestones, the company is optimistic that NASARIX™ may potentially evolve into a welcome new option for allergy sufferers looking for better everyday protection.

Looking Ahead

In short, NASARIX™ has evidenced solid conceptual promise as a preventive, user-friendly addition to allergy care. Early 2026 milestones, like branding and usability work, keep the program advancing. The real test will come with human trial results, which are expected to commence later this year.

Paid Promotional Disclosure

This press release constitutes a paid promotional communication. Polyrizon Ltd.. ("Polyrizon") has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this press release, and has paid a fee for such services. Polyrizon exercises editorial control over the content of this press release but does not control how, when, or to whom the information is distributed by such third party.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Polyrizon. Investing in Polyrizon's securities involves significant risks, and readers are encouraged to review Polyrizon's filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.
For more information about Polyrizon, please visit https://polyrizon-biotech.com.

Moonage Media- Disclaimer

This article was produced by Moonage Media, a brand / division of MR Solutions Limited (Hong Kong), and is provided for general informational and promotional purposes only. The content does not constitute investment advice, financial advice, medical advice, or a recommendation to buy, sell, or hold any securities, nor does it constitute an offer or solicitation in any jurisdiction.

Moonage Media is not a registered broker-dealer, investment adviser, securities analyst, or medical professional. The information presented is based on publicly available sources and statements believed to be reliable at the time of publication; however, Moonage Media makes no representations or warranties as to the accuracy or completeness of the information and has not independently verified all data referenced.

Certain content published by Moonage Media may be sponsored or compensated by the company discussed or its affiliates, which may create a potential conflict of interest. Readers are encouraged to conduct their own independent research and consult qualified financial, legal, medical, or other professional advisers before making any investment or health-related decisions.

Forward-looking statements referenced in this article are subject to risks and uncertainties, and actual results may differ materially. Past performance is not indicative of future results.

For full disclosures, risk factors, and forward-looking statements, please visit: https://moonage.media/disclaimer/

Contact:

Moonage Media
Office@Moonage.media 

View original content:https://www.prnewswire.com/news-releases/moonage-media-spotlights-polyrizon-nasdaq-plrz-unveils-nasarix-drug-free-allergy-blocker-302689664.html

SOURCE Moonage Media

FAQ

What is NASARIX™ from Polyrizon (PLRZ) and how does it work?

NASARIX™ is a drug‑free intranasal spray that forms a bio‑adhesive barrier to trap allergens before they reach nasal tissue. According to the company, it uses Capture and Contain™ hydrogel to physically capture pollen, dust mites, and pet dander as a preventive approach.

When did Polyrizon (PLRZ) start human usability testing for NASARIX™?

Polyrizon began a human factors and usability study on January 22, 2026 to validate instructions and labeling. According to the company, this study aligns with FDA guidance and aims to strengthen the regulatory foundation ahead of clinical trials.

When are clinical trials for NASARIX™ (PLRZ) expected to begin?

Polyrizon expects to commence human clinical trials in Q3 2026 for NASARIX™. According to the company, this timing follows completion of usability work and supports a potential medical device regulatory pathway toward patient access.

Does Polyrizon (PLRZ) have human efficacy data for NASARIX™ yet?

No, NASARIX™ currently has only preclinical efficacy data showing superior allergen blocking versus comparators. According to the company, human clinical efficacy and safety data are expected once trials start later in 2026.

What regulatory route is Polyrizon (PLRZ) pursuing for NASARIX™ and why does it matter?

Polyrizon is positioning NASARIX™ as a medical device to pursue a more streamlined approval path versus drugs. According to the company, this could shorten time to market if device regulatory requirements are met and trials support clearance.